Massachusetts Financial Services Company Upped Its Facebook (FB) Holding; Quest Diagnostics (DGX) Sentiment Is 0.92

March 22, 2018 - By Louis Casey

Massachusetts Financial Services Company increased Facebook Inc (FB) stake by 0.18% reported in 2017Q3 SEC filing. Massachusetts Financial Services Company acquired 23,506 shares as Facebook Inc (FB)’s stock rose 10.88%. The Massachusetts Financial Services Company holds 13.14 million shares with $2.25 billion value, up from 13.12M last quarter. Facebook Inc now has $483.60 billion valuation. The stock decreased 1.72% or $2.92 during the last trading session, reaching $166.47. About 59.23 million shares traded or 121.39% up from the average. Facebook, Inc. (NASDAQ:FB) has risen 26.75% since March 22, 2017 and is uptrending. It has outperformed by 10.05% the S&P500.

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company has market cap of $14.01 billion. The companyÂ’s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, gene and esoteric testing, and drugs-of-abuse testing, as well as anatomic pathology services, and related services and insights. It has a 18.78 P/E ratio. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum, and Care360 brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, and phlebotomists in physician offices.

Investors sentiment increased to 1.21 in 2017 Q3. Its up 0.06, from 1.15 in 2017Q2. It increased, as 53 investors sold FB shares while 618 reduced holdings. 128 funds opened positions while 644 raised stakes. 1.63 billion shares or 0.88% more from 1.62 billion shares in 2017Q2 were reported. Charter Tru has invested 0.04% in Facebook, Inc. (NASDAQ:FB). Moreover, Highvista Strategies Llc has 0.77% invested in Facebook, Inc. (NASDAQ:FB) for 19,800 shares. Argent Capital Mgmt Limited Liability holds 2.2% of its portfolio in Facebook, Inc. (NASDAQ:FB) for 333,699 shares. The South Carolina-based Colonial Trust Advisors has invested 0.05% in Facebook, Inc. (NASDAQ:FB). Philadelphia Tru has 2.33% invested in Facebook, Inc. (NASDAQ:FB) for 166,219 shares. 48,785 were accumulated by Ahl Ltd Liability Partnership. Point72 Asia (Hong Kong) accumulated 1,057 shares or 0.13% of the stock. Neumann Cap Limited Liability owns 1,310 shares. Pointstate Cap LP owns 4.1% invested in Facebook, Inc. (NASDAQ:FB) for 2.82 million shares. First Republic Investment Mngmt Incorporated invested 1.49% of its portfolio in Facebook, Inc. (NASDAQ:FB). Moreover, Greenleaf has 0.05% invested in Facebook, Inc. (NASDAQ:FB). Wedge Capital Management L Limited Partnership Nc accumulated 1,663 shares or 0% of the stock. 5,657 were reported by Jefferies Group Limited Liability Corp. Tiedemann Wealth Management Limited Liability Co holds 24,766 shares. Sg Americas Ltd has invested 0.12% in Facebook, Inc. (NASDAQ:FB).

Massachusetts Financial Services Company decreased Noble Energy Inc (NYSE:NBL) stake by 655,193 shares to 1.52 million valued at $43.17 million in 2017Q3. It also reduced Energen Corp (NYSE:EGN) stake by 524,731 shares and now owns 1.56 million shares. Bard C R Inc (NYSE:BCR) was reduced too.

Among 55 analysts covering Facebook (NASDAQ:FB), 51 have Buy rating, 2 Sell and 2 Hold. Therefore 93% are positive. Facebook had 239 analyst reports since July 21, 2015 according to SRatingsIntel. On Thursday, January 25 the stock rating was maintained by GBH Insights with “Buy”. The rating was maintained by KeyBanc Capital Markets with “Buy” on Tuesday, October 3. The firm has “Overweight” rating by Piper Jaffray given on Tuesday, August 18. Raymond James maintained it with “Strong Buy” rating and $215 target in Thursday, July 27 report. The stock of Facebook, Inc. (NASDAQ:FB) earned “Outperform” rating by Wells Fargo on Thursday, November 3. Wells Fargo maintained the stock with “Buy” rating in Wednesday, September 27 report. The rating was maintained by SunTrust on Friday, January 12 with “Buy”. As per Wednesday, September 6, the company rating was maintained by KeyBanc Capital Markets. The rating was maintained by FBR Capital with “Outperform” on Thursday, July 30. Canaccord Genuity maintained Facebook, Inc. (NASDAQ:FB) on Thursday, December 1 with “Buy” rating.

Since September 26, 2017, it had 0 insider buys, and 39 selling transactions for $1.14 billion activity. Another trade for 38,024 shares valued at $6.94 million was sold by Schroepfer Michael Todd. 220,000 shares valued at $39.03 million were sold by Zuckerberg Mark on Wednesday, February 14. Cox Christopher K sold $2.83 million worth of Facebook, Inc. (NASDAQ:FB) on Thursday, December 7. $127,573 worth of Facebook, Inc. (NASDAQ:FB) was sold by Stretch Colin on Tuesday, October 3. $806,019 worth of Facebook, Inc. (NASDAQ:FB) was sold by FISCHER DAVID B.. The insider Sandberg Sheryl sold $10.07 million. Shares for $221.33 million were sold by Koum Jan.

The stock decreased 0.33% or $0.34 during the last trading session, reaching $103.29. About 441,188 shares traded. Quest Diagnostics Incorporated (DGX) has risen 39.04% since March 22, 2017 and is uptrending. It has outperformed by 22.34% the S&P500.

Since January 1, 0001, it had 0 insider purchases, and 13 selling transactions for $30.90 million activity.

Ratings analysis reveals 67% of Quest Diagnostics’s analysts are positive. Out of 6 Wall Street analysts rating Quest Diagnostics, 4 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $86.0 while the high is $110.0. The stock’s average target of $98.50 is -4.64% below today’s ($103.29) share price. DGX was included in 6 notes of analysts from August 31, 2016. The stock has “Neutral” rating by Mizuho on Wednesday, August 31. The stock has “Buy” rating by Goldman Sachs on Monday, December 12. The firm has “Outperform” rating given on Wednesday, April 12 by FBR Capital. As per Wednesday, January 18, the company rating was initiated by Deutsche Bank. The rating was upgraded by UBS on Monday, November 14 to “Buy”. The rating was initiated by Citigroup with “Neutral” on Friday, September 9.

Weybosset Research & Management Llc holds 2.32% of its portfolio in Quest Diagnostics Incorporated for 37,277 shares. Financial Advantage Inc. owns 30,351 shares or 2.31% of their US portfolio. Moreover, Polaris Capital Management Llc has 1.98% invested in the company for 377,297 shares. The Connecticut-based Northcoast Asset Management Llc has invested 1.91% in the stock. Stellar Capital Management Llc, a Arizona-based fund reported 28,513 shares.

Analysts await Quest Diagnostics Incorporated (NYSE:DGX) to report earnings on April, 19. They expect $1.54 EPS, up 15.79% or $0.21 from last year’s $1.33 per share. DGX’s profit will be $208.88M for 16.77 P/E if the $1.54 EPS becomes a reality. After $1.38 actual EPS reported by Quest Diagnostics Incorporated for the previous quarter, Wall Street now forecasts 11.59% EPS growth.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: